Authorised Representative (AR) System: Legal Basis and Duties of Jordan’s Mandatory Local Representative

1. Key takeaways

Jordan requires, on a mandatory statutory basis, that every foreign medical device manufacturer appoint a locally licensed company established inside Jordan to act as its authorised representative (AR). GRZAN’s conclusion is unambiguous: this is not an optional commercial arrangement but a legal precondition. Without an AR, a foreign manufacturer cannot enter any procedure of the Jordan Food and Drug Administration (JFDA) at all, because the regulator deals with foreign applicants only through this locally licensed entity. In practice, the choice of AR is therefore made before any other step of the Jordanian project can move, because the appointment determines who files, who signs, who receives official correspondence and who answers the authority.

• Second conclusion: the AR is the single channel for the entire process. Registration submissions, delivery of samples, post-market vigilance reports and customs clearance documents must all be handled through the AR’s bound account in the JFDA system. There is no direct dialogue channel between the manufacturer and the JFDA.
• Third conclusion: the AR is usually also the importer and distributor, forming a dual role. This brings efficiency, because one relationship solves registration and import at the same time, but it also creates lock-in risk: replacing the AR means migrating the registration certificate to a new holder. The replacement decision therefore deserves the same diligence as the original selection.
• Fourth conclusion: the statutory duties of the AR cover the full product lifecycle, spanning pre-market submission and post-market surveillance. This makes the appointment a continuous regulatory function, not a file-once-and-forget arrangement.

2. Legal basis

The designation and the duties of the local authorised representative rest on the following instruments.

Clause numbers must be verified against the Arabic originals published in the Official Gazette of Jordan and issued by the JFDA.

3. Expert insights

Insight 1: the statutory duties of the AR cover the entire lifecycle. The AR submits registration applications on behalf of the manufacturer, provides and maintains the technical and regulatory documentation, manages official communication with the authority, and handles post-market surveillance, complaints and vigilance activities. These four duties run across both the pre-market and the post-market phases, which means the appointment is a continuous regulatory function rather than a role that ends once a dossier has been filed. A manufacturer that treats the appointment as a one-off signature loses visibility of its own registration, because every later action — a deficiency response, a vigilance notification, a change filing — runs through the AR’s bound account.

Insight 2: the qualification threshold of the AR is defined through commercial registration. An AR must hold a commercial registration certificate issued by the Ministry of Industry and Trade whose registered scope covers the import of medical devices or medical consumables. In addition, the AR must open an account in the JFDA system and bind to that account a warehouse that has passed JFDA on-site acceptance, operated as a Scientific Office / Warehouse. Both conditions can be verified in advance: the registered business scope can be read directly from the certificate, and the acceptance status of the warehouse can be confirmed from the JFDA acceptance documentation.

Insight 3: the consequences of choosing the wrong AR are chained. Industry material summarises four categories of consequences: registration rejection, import suspension, product recall and administrative penalty. These four are not parallel risks but a progressive chain, because problems that arise at the registration stage carry through into the import stage and the post-market stage. Each stage widens the damage: a question that begins at the review desk becomes an import blockage, and an unresolved import issue becomes a market-level enforcement matter.

Insight 4: replacing an AR involves migration of the registration certificate. Because the registration is bound to a specific physical warehouse, a change of AR usually entails migration or re-issuance of the certificate. The cost of trial and error when selecting an AR is therefore far higher in Jordan than in most other markets. This is why the replacement mechanism, the migration duty and the transition arrangements belong in the agreement from the outset, not in a renegotiation after the relationship has broken down.

Insight 5: the dual role of the AR creates a conflict of interest. The same entity acts both as regulatory representative and as commercial distributor, so the effort it invests in pushing a registration forward depends on its expectation of commercial return. GRZAN recommends containing this risk through registration-progress clauses written into the agreement.

4. Practical recommendations

• Treat AR selection as a compliance decision. The core due diligence items are the scope of the commercial registration, the status of the JFDA system account, the acceptance status of the warehouse, the capability to handle vigilance, and experience with comparable products.
• Specify in the agreement the performance standards and the time limits for the four statutory duties, with particular attention to the response times for vigilance reporting and for change notification.
• Agree the AR replacement mechanism in advance, covering the trigger conditions for replacement, the duty to cooperate in migrating the registration certificate, and the arrangements for the transition period.
• Link registration progress to commercial terms, using registration milestones as conditions for continuing exclusivity or for releasing fee payments.

5. Verification checklist

• □ Confirm that a licensed AR inside Jordan has been appointed in writing, with no exceptions
• □ Verify that the AR’s commercial registration covers the import of devices or consumables
• □ Verify that the AR holds a JFDA system account bound to a warehouse that has passed acceptance
• □ Confirm that the agreement sets performance standards and time limits for the four statutory duties
• □ Confirm that the agreement contains an AR replacement mechanism and certificate migration arrangements
• □ Confirm that clauses linking registration progress to commercial terms are in place
• □ Re-verify the cited clause numbers against the Arabic originals of the Official Gazette

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com